Experimental group:Radiotherapy

6 trials

Sponsors

Shandong Cancer Hospital, First Medical Center of the Chinese PLA General Hospital, Chongqing Shapingba District People's Hospital, Mianyang Central Hospital, Xuzhou Central Hospital

Conditions

Breast cancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaTreatment-Naive EGFR-MutatedOligometastatic Non-Small Cell Lung Cancerepithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinomanon-small-cell lung cancer

Early Phase 1

Exploratory study of PD-L1/TGF-ßRII bifunctional antibody combined with radiotherapy as neoadjuvant therapy for esophageal squamous cell carcinoma

RecruitingChiCTR2000041562

Shandong Cancer HospitalEsophageal Squamous Cell Carcinoma

Start: 2021-01-01Updated: 2021-03-15

A clinical study of radiation-induced regulation of TLS-B cell activation during immune checkpoint inhibitor therapy in patients with advanced NSCLC

Active, not recruitingChiCTR2200057825

Chongqing Shapingba District People's Hospitalnon-small-cell lung cancer

Start: 2022-06-01Updated: 2023-11-13

Phase 2

The efficacy and safety of PARP inhibitor maintenance therapy combined with local radiotherapy for recurrent and metastatic tumors of epithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma

Active, not recruitingChiCTR2300068539

Mianyang Central Hospitalepithelial ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma

Start: 2023-03-01Updated: 2023-05-22

Phase 3

Aumolertinib with or without Radiotherapy for Treatment-Naïve EGFR-Mutated Oligometastatic Non-Small Cell Lung Cancer: A Phase III, Multicenter, Open-Label, Randomized Controlled Trial

Active, not recruitingChiCTR2600121546

West China Hospital of Sichuan UniversityTreatment-Naive EGFR-MutatedOligometastatic Non-Small Cell Lung Cancer

Start: 2026-04-01Updated: 2026-04-14

Unknown Phase

Development and Validation of Prediction Model for Xerostomia Following Iiradiation in Head and Neck Squamous Cell Carcinoma: a Prospective Study

RecruitingChiCTR2100045198

First Medical Center of the Chinese PLA General HospitalHead and Neck Squamous Cell Carcinoma

Start: 2021-05-01Updated: 2021-11-08

Application Study of Adaptive Radiotherapy for Cardiac Protection in Thoracic Malignancies

Active, not recruitingChiCTR2400094837

Xuzhou Central HospitalBreast cancer

Start: 2025-01-01Updated: 2025-01-06

Related Papers

Neoadjuvant SHR-1701 (a bifunctional anti-PD-L1/TGF-βRII agent) combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A phase II trial.

Journal of Clinical Oncology2025-01-27